Paul T. Francis
#159,973
Most Influential Person Now
Researcher
Paul T. Francis's AcademicInfluence.com Rankings
Paul T. Francisphysics Degrees
Physics
#7328
World Rank
#9350
Historical Rank
Astrophysics
#612
World Rank
#657
Historical Rank
Astronomy
#978
World Rank
#1624
Historical Rank
Paul T. Francismathematics Degrees
Mathematics
#7323
World Rank
#9973
Historical Rank
Number Theory
#241
World Rank
#307
Historical Rank
Measure Theory
#2055
World Rank
#2491
Historical Rank
Download Badge
Physics Mathematics
Paul T. Francis's Degrees
- Masters Astronomy University of California, Berkeley
- Bachelors Mathematics Stanford University
Similar Degrees You Can Earn
Why Is Paul T. Francis Influential?
(Suggest an Edit or Addition)Paul T. Francis's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The cholinergic hypothesis of Alzheimer’s disease: a review of progress (1999) (1688)
- Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. (2010) (385)
- Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment. (1985) (355)
- Cholinesterase Inhibitors Used in the Treatment of Alzheimer’s Disease (2004) (301)
- Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future (2013) (288)
- Glutamatergic systems in Alzheimer's disease (2003) (231)
- Cortical Pyramidal Neurone Loss May Cause Glutamatergic Hypoactivity and Cognitive Impairment in Alzheimer's Disease: Investigative and Therapeutic Perspectives (1993) (230)
- AddNeuroMed—The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease (2009) (203)
- Cholinergic–serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer’s disease (2005) (201)
- The Interplay of Neurotransmitters in Alzheimer's Disease (2005) (199)
- Monoaminergic innervation of the frontal and temporal lobes in Alzheimer's disease (1987) (188)
- Metals ions and neurodegeneration (2007) (185)
- Noradrenergic changes, aggressive behavior, and cognition in patients with dementia (2002) (184)
- Cholinergic deficits contribute to behavioral disturbance in patients with dementia (2000) (169)
- Down‐regulation of vesicular glutamate transporters precedes cell loss and pathology in Alzheimer's disease (2006) (166)
- Apathy associated with neurocognitive disorders: Recent progress and future directions (2017) (163)
- Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias (2014) (154)
- Circumscribed changes of the cerebral cortex in neuropsychiatric disorders of later life. (1989) (149)
- Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial (2012) (147)
- Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease (2003) (146)
- Topographical distribution of neurochemical changes in Alzheimer's disease (1988) (146)
- A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease? (2005) (144)
- CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients (2013) (141)
- Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach (2018) (140)
- Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies (2007) (133)
- Catecholaminergic neurones assessed ante-mortem in Alzheimer's disease (1987) (132)
- Presynaptic Serotonergic Markers in Community‐Acquired Cases of Alzheimer's Disease: Correlations with Depression and Neuroleptic Medication (1996) (131)
- Differential Involvement of 5-HT1B/1D and 5-HT6 Receptors in Cognitive and Non-cognitive Symptoms in Alzheimer's Disease (2004) (130)
- Gamma-aminobutyric acid concentration in brain tissue at two stages of Alzheimer's disease. (1988) (127)
- Neurochemical Features of Frontotemporal Dementia (1999) (127)
- Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia (2016) (117)
- A Double-Blind Placebo-Controlled Randomized Trial of Melissa officinalis Oil and Donepezil for the Treatment of Agitation in Alzheimer’s Disease (2011) (111)
- Psychosis of Alzheimer’s disease is associated with elevated muscarinic M2 binding in the cortex (2001) (110)
- Immunocytochemical study of the dorsal and median raphe nuclei in patients with Alzheimer’s disease prospectively assessed for behavioural changes (2000) (101)
- Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer's disease: association with cognitive impairment (2014) (97)
- Brain amino acid concentrations and Ca2+-dependent release in intractable depression assessed antemortem (1989) (97)
- Calsyntenin-1 mediates axonal transport of the amyloid precursor protein and regulates Aβ production (2012) (95)
- Neurochemical basis for symptomatic treatment of Alzheimer's disease (2010) (92)
- Loss of serotonin 5-HT2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer’s disease (2005) (91)
- Impaired coupling of muscarinic M1 receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease (2006) (90)
- Ante mortem cerebral amino acid concentrations indicate selective degeneration of glutamate-enriched neurons in Alzheimer's disease (1990) (89)
- Identification of Novel α-Synuclein Isoforms in Human Brain Tissue by using an Online NanoLC-ESI-FTICR-MS Method (2011) (88)
- 5-Hydroxytryptamine1A but not 5-hydroxytryptamine2 receptors are enriched on neocortical pyramidal neurones destroyed by intrastriatal volkensin. (1992) (79)
- Postmortem serotoninergic correlates of cognitive decline in Alzheimer's disease (2002) (79)
- Synaptic Pathology in Prefrontal Cortex is Present Only with Severe Dementia in Alzheimer Disease (2001) (78)
- Dietary (−)-epicatechin as a potent inhibitor of βγ-secretase amyloid precursor protein processing (2015) (75)
- Putative amino acid transmitters in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer's dementia. (1985) (74)
- Serotonin 5-HT6 Receptor Antagonists in Alzheimer’s Disease: Therapeutic Rationale and Current Development Status (2016) (72)
- Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY‐5Y cells (2008) (72)
- Serotonergic Therapies for Cognitive Symptoms in Alzheimer’s Disease: Rationale and Current Status (2014) (72)
- Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson's disease neocortex. (1998) (71)
- Recalibrating the epigenetic clock: implications for assessing biological age in the human cortex (2020) (70)
- Stage-Specific Changes in Neurogenic and Glial Markers in Alzheimer’s Disease (2015) (69)
- The effects of perturbed energy metabolism on the processing of amyloid precursor protein in PC12 cells (1998) (69)
- Corrigendum: Macrophage Migration Inhibitory Factor is subjected to glucose modification and oxidation in Alzheimer’s Disease (2017) (68)
- d-Cycloserine, a putative cognitive enhancer, facilitates activation of the N-methyl-d-aspartate receptor-ionophore complex in Alzheimer brain (1991) (67)
- Aβ1–42 modulation of Akt phosphorylation via α7 nAChR and NMDA receptors (2008) (66)
- Dementia in Parkinson's disease is associated with enhanced mitochondrial complex I deficiency (2016) (65)
- Cholinergic imbalance in the multiple sclerosis hippocampus (2011) (65)
- Imbalance of a serotonergic system in frontotemporal dementia: implication for pharmacotherapy (2008) (64)
- Preliminary neurochemical findings in non-Alzheimer dementia due to lobar atrophy. (1993) (64)
- Involvement of the GABAergic system in depressive symptoms of Alzheimer's disease (2006) (63)
- The 5-HT1A antagonist, WAY 100635, ameliorates the cognitive impairment induced by fornix transection in the marmoset (1996) (61)
- Neuropsychiatric Symptoms in Patients with Dementias Associated with Cortical Lewy Bodies: Pathophysiology, Clinical Features, and Pharmacological Management (2013) (61)
- Neurochemical studies of early-onset Alzheimerʼs disease (1987) (60)
- Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management (2020) (59)
- Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex (2010) (59)
- Somatostatin content and release measured in cerebral biopsies from demented patients (1987) (59)
- Pharmacological profile of essential oils derived from Lavandula angustifolia and Melissa officinalis with anti‐agitation properties: focus on ligand‐gated channels (2009) (59)
- Altered glutamate neurotransmission and behaviour in dementia: evidence from studies of memantine. (2009) (56)
- Alzheimer’s disease polygenic risk score as a predictor of conversion from mild-cognitive impairment (2019) (53)
- Ketamine sedation for children in the emergency department. (2001) (52)
- Treatment strategies for Alzheimer's disease (1992) (51)
- Age-related alteration in excitatory amino acid neurotransmission in rat brain (1990) (51)
- Selective loss of P2Y2 nucleotide receptor immunoreactivity is associated with Alzheimer’s disease neuropathology (2008) (49)
- A rare loss-of-function variant of ADAM17 is associated with late-onset familial Alzheimer disease (2018) (45)
- Pharmacological profile of an essential oil derived from Melissa officinalis with anti‐agitation properties: focus on ligand‐gated channels (2008) (45)
- A meta-analysis of epigenome-wide association studies in Alzheimer’s disease highlights novel differentially methylated loci across cortex (2020) (44)
- Unfolded protein response is activated in Lewy body dementias (2016) (44)
- Somatostatin-like immunoreactivity in lumbar cerebrospinal fluid from neurohistologically examined demented patients (1984) (43)
- Depression and synaptic zinc regulation in Alzheimer disease, dementia with lewy bodies, and Parkinson disease dementia. (2015) (41)
- Synthesis, physical-chemical characterisation and biological evaluation of novel 2-amido-3-hydroxypyridin-4(1H)-ones: Iron chelators with the potential for treating Alzheimer's disease. (2011) (41)
- Lysosomal cathepsin D is upregulated in Alzheimer's disease neocortex and may be a marker for neurofibrillary degeneration (2018) (40)
- Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer’s disease (2012) (40)
- Differential involvement of hippocampal serotonin1A receptors and re-uptake sites in non-cognitive behaviors of Alzheimer’s disease (2011) (40)
- Cortical Serotonin 1A Receptor Levels Are Associated with Depression in Patients with Dementia with Lewy Bodies and Parkinson’s Disease Dementia (2008) (40)
- “Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene-dose-sensitive AD-suppressor in human brain” (2020) (40)
- Glutamatergic Approaches to the Treatment of Cognitive and Behavioural Symptoms of Alzheimer’s Disease (2008) (39)
- Aggressive behavior and neuroleptic medication are associated with increased number of alpha1-adrenoceptors in patients with Alzheimer disease. (2007) (39)
- Vesicular glutamate transporter and cognition in stroke (2010) (39)
- Animal and drug modelling for Alzheimer synaptic pathology (1992) (39)
- Whole‐exome sequencing of the BDR cohort: evidence to support the role of the PILRA gene in Alzheimer's disease (2018) (39)
- Altered NCAM expression associated with the cholinergic system in Alzheimer's disease. (2010) (38)
- Involvement of an altered 5-HT -{6} receptor function in behavioral symptoms of Alzheimer's disease. (2008) (38)
- A novel protein, amyloid precursor-like protein 2, is present in human brain, cerebrospinal fluid and conditioned media. (1995) (37)
- Characterisation of the Glycine Modulatory Site of the N‐Methyl‐d‐Aspartate Receptor‐Ionophore Complex in Human Brain (1991) (37)
- Abeta(1-42) modulation of Akt phosphorylation via alpha7 nAChR and NMDA receptors. (2008) (37)
- Tau phosphorylation in human brain: relationship to behavioral disturbance in dementia (2012) (37)
- Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson's disease and Lewy body dementias: Review and meta‐analyses (2018) (36)
- Increased binding to 5-HT1A and 5-HT2A receptors is associated with large vessel infarction and relative preservation of cognition. (2009) (36)
- Macrophage Migration Inhibitory Factor is subjected to glucose modification and oxidation in Alzheimer’s Disease (2017) (35)
- Inflammatory Mediators in the Frontal Lobe of Patients with Mixed and Vascular Dementia (2008) (34)
- Pro-oxidant diet enhances β/γ secretase-mediated APP processing in APP/PS1 transgenic mice (2012) (34)
- Localisation of muscarinic (m1) and other neurotransmitter receptors on corticofugal-projecting pyramidal neurones (1993) (34)
- Clusterin Associates Specifically with Aβ40 in Alzheimer's Disease Brain Tissue (2013) (34)
- A serotoninergic basis for hyperphagic eating changes in Alzheimer's disease (2010) (34)
- Choline Acetyltransferase Activity in Vascular Dementia and Stroke (2009) (33)
- Biochemical and pathological correlates of cognitive and behavioural change in DLB/PDD (2009) (33)
- Neurotransmission—the link integrating Alzheimer research? (1994) (33)
- Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms (1992) (33)
- Amyloid β concentrations in older people with Down syndrome and dementia (2009) (33)
- Are post-mortem biochemical studies of human brain worthwhile? (1988) (33)
- Novel pathophysiological markers are revealed by iTRAQ-based quantitative clinical proteomics approach in vascular dementia (2014) (31)
- Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain (2020) (31)
- Neurotransmitters and Second Messengers in Aging and Alzheimer's Disease (1993) (30)
- Cyclin-dependent kinase 5, Munc18a and Munc18-interacting protein 1/X11α protein up-regulation in Alzheimer’s disease (2006) (30)
- Expression of Amyloid precursor protein, tau and presenilin RNAs in rat hippocampus following deafferentation lesions (2001) (29)
- Effect of Central Cholinergic Stimulation on Regional Cerebral Blood Flow in Alzheimer's Disease (1991) (29)
- Decreased Levels of VAMP2 and Monomeric Alpha-Synuclein Correlate with Duration of Dementia. (2015) (29)
- Selective effects of the APOE ε4 allele on presynaptic cholinergic markers in the neocortex of Alzheimer's disease (2006) (29)
- Destruction of a sub-population of cortical neurones by suicide transport of volkensin, a lectin from Adenia volkensii (1991) (29)
- Association of a polymorphism in mitochondrial transcription factor A (TFAM) with Parkinson's disease dementia but not dementia with Lewy bodies (2013) (29)
- [3H]GR113808 binding to serotonin 5-HT4 receptors in the postmortem neocortex of Alzheimer disease: a clinicopathological study (2003) (27)
- Antemortem measurements of neurotransmission: possible implications for pharmacotherapy of Alzheimer's disease and depression. (1993) (27)
- Concomitant neurodegenerative pathologies contribute to the transition from mild cognitive impairment to dementia (2021) (26)
- Increased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with β-amyloid burden and synaptic deficits in Lewy body dementias (2016) (26)
- An iTRAQ-based proteomic analysis reveals dysregulation of neocortical synaptopodin in Lewy body dementias (2017) (25)
- Decreased rabphilin 3A immunoreactivity in Alzheimer’s disease is associated with Aβ burden (2014) (25)
- ‘Traditional’ pharmacotherapy may succeed in Alzheimer's disease (1992) (24)
- Postmortem Cortical Transcriptomics of Lewy Body Dementia Reveal Mitochondrial Dysfunction and Lack of Neuroinflammation. (2020) (24)
- Targeting Cell Death in Dementia (2006) (22)
- Spermidine enhancement of [3H]MK-801 binding to the NMDA receptor complex in human cortical membranes. (1990) (22)
- The dementia of Alzheimer's disease: an update. (1987) (22)
- Effect of Psychotropic Drugs on Excitatory Amino Acids in Patients Undergoing Psychosurgery for Depression (1992) (21)
- Genetic Associations of Autopsy-Confirmed Vascular Dementia Subtypes (2011) (21)
- Memantine potentiates hippocampal theta oscillations at a therapeutic dose in anesthetized mice: A mechanistic link to its cognitive-enhancing properties (2012) (21)
- Dynamin1 concentration in the prefrontal cortex is associated with cognitive impairment in Lewy body dementia (2014) (21)
- Brains for Dementia Research: Evolution in a Longitudinal Brain Donation Cohort to Maximize Current and Future Value (2018) (20)
- Pyramidal neurone modulation: a therapeutic target for Alzheimer's disease. (1996) (19)
- NMDA receptors assessed by autoradiography with [3H]L-689,560 are present but not enriched on corticofugal-projecting pyramidal neurones (1992) (19)
- Serotonin transporters are preserved in the neocortex of anxious Alzheimer's disease patients (2003) (19)
- Increased Levels of Brain Adrenomedullin in the Neuropathology of Alzheimer’s Disease (2018) (19)
- Assisted ventilation in neonates: The Manipal experience (1994) (18)
- Cholinergic and glutamatergic drugs in Alzheimer’s disease therapy (2005) (17)
- α-synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies (2009) (17)
- Increased Transforming Growth Factor β2 in the Neocortex of Alzheimer's Disease and Dementia with Lewy Bodies is Correlated with Disease Severity and Soluble Aβ42 Load. (2017) (17)
- An isoform‐specific role of FynT tyrosine kinase in Alzheimer's disease (2016) (16)
- Tacrine, a Drug with Therapeutic Potential for Dementia: Post-Mortem Biochemical Evidence (1989) (16)
- Isoform‐specific upregulation of FynT kinase expression is associated with tauopathy and glial activation in Alzheimer's disease and Lewy body dementias (2020) (15)
- Reduction of RPT6/S8 (a Proteasome Component) and Proteasome Activity in the Cortex is Associated with Cognitive Impairment in Lewy Body Dementia (2017) (15)
- Loss of [3H]4-DAMP binding to muscarinic receptors in the orbitofrontal cortex of Alzheimer’s disease patients with psychosis (2008) (14)
- Neurochemistry of Aging (2006) (14)
- Disturbed Matrix Metalloproteinase Pathway in Both Age-Related Macular Degeneration and Alzheimer's Disease (2017) (14)
- Importance of Proactive Treatment of Depression in Lewy Body Dementias: The Impact on Hippocampal Neurogenesis and Cognition in a Post-Mortem Study (2018) (14)
- The 5-HT1A antagonist, WAY 100635, ameliorates the cognitive impairment induced by fornix transection in the marmoset (2005) (13)
- Neurotransmitter and Metabolic Dysfunction in Alzheimer’s Dementia: Relationship to Histopathological Features (1985) (13)
- Postmortem brains reveal similar but not identical amyloid precursor protein-like immunoreactivity in Alzheimer compared with other dementias (1994) (13)
- Changes in hippocampal SNAP-25 expression following afferent lesions (2004) (12)
- Associations between ZnT3, tau pathology, agitation, and delusions in dementia (2018) (12)
- Proteasome inhibition leads to early loss of synaptic proteins in neuronal culture (2012) (12)
- Mitochondrial Translocase of the Outer Membrane Alterations May Underlie Dysfunctional Oxidative Phosphorylation in Alzheimer's Disease. (2017) (12)
- Regional mitochondrial DNA and cell-type changes in post-mortem brains of non-diabetic Alzheimer’s disease are not present in diabetic Alzheimer’s disease (2019) (12)
- Pyramidal neuron loss and “glycine-site therapy”: A need for an animal model and study in late-life depression (1989) (11)
- Relevance of reduced concentrations of somatostatin in Alzheimer's disease (1985) (11)
- 5-HT1B and other related serotonergic proteins are altered in APPswe mutation (2015) (11)
- Pharmacological profile of essential oils derived from Lavandula angustifolia and Melissa officinalis with anti‐agitation properties: focus on ligand‐gated channels (2008) (11)
- Cyclin-dependent kinase 5, Munc18a and Munc18-interacting protein 1/X11alpha protein up-regulation in Alzheimer's disease. (2006) (11)
- Brain membrane serine protease activity in human cortex compared with rat: implication for Alzheimer's disease. (1994) (11)
- Neuropsychiatric symptoms in limbic-predominant age-related TDP-43 encephalopathy and Alzheimer’s disease (2020) (10)
- Ticking boxes or meaningful partnership – The experience of lay representation, participant and study partner involvement in Brains for Dementia Research (2018) (9)
- Altered relaxin family receptors RXFP1 and RXFP3 in the neocortex of depressed Alzheimer’s disease patients (2016) (9)
- Changes in cortical nicotinic acetylcholine receptor numbers following unilateral destruction of pyramidal neurones by intrastriatal volkensin injection. (1995) (9)
- DNA methylation signatures of Alzheimer’s disease neuropathology in the cortex are primarily driven by variation in non-neuronal cell-types (2022) (9)
- Neurochemical pathology of dementia with Lewy bodies (2006) (8)
- Observations of extensive gene expression differences in the cerebellum and potential relevance to Alzheimer’s disease (2018) (8)
- Age-related neurochemical and behavioural changes in D409V/WT GBA1 mouse: Relevance to lewy body dementia (2019) (8)
- Treatment of Alzheimer's disease. (1992) (8)
- Dynamin 1 concentration in the prefrontal cortex is associated with cognitive impairment in Lewy body dementia (2015) (8)
- Protection from dementia. (1992) (8)
- Soluble β-amyloid precursor protein and pyramidal neuron loss (1993) (8)
- Pharmacological Modulations of the Serotonergic System in a Cell-Model of Familial Alzheimer's Disease. (2016) (8)
- Clinical correlations of the neurobiological changes of aging. (1990) (7)
- Antipsychotic medication is associated with selective alterations in ventricular cerebrospinal fluid Aβ 40 and tau in patients with intractable unipolar depression (2011) (7)
- Cerebral amyloid angiopathy distribution in older people: A cautionary note (2021) (7)
- Genotyping of the Alzheimer's Disease Genome-Wide Association Study Index Single Nucleotide Polymorphisms in the Brains for Dementia Research Cohort. (2018) (7)
- Striatal Dopaminergic Deficit and Sleep in Idiopathic Rapid Eye Movement Behaviour Disorder: An Explorative Study (2021) (7)
- Genetic variants in glutamate-, Aβ−, and tau-related pathways determine polygenic risk for Alzheimer's disease (2020) (7)
- Neurotransmitter receptors of rat cortical pyramidal neurones: implications for in vivo imaging and therapy. (1993) (7)
- Lack of Change in Neurochemical Markers During the Postepileptic Phase of Intrahippocampal Tetanus Toxin Syndrome in Rats (1990) (7)
- Neurochemical changes in a double transgenic mouse model of Alzheimer's disease fed a pro-oxidant diet (2010) (7)
- β-Amyloid precursor protein isoforms show correlations with neurones but not with glia of demented subjects (2004) (7)
- The effect of phloretin on synaptic proteins and adult hippocampal neurogenesis in Aβ (1‐42)‐injected male Wistar rats (2018) (6)
- beta-Amyloid increased neuronal susceptibility to injury by glucose deprivation. (1992) (6)
- The stability of 5-hydroxyindoleacetic acid and noradrenaline in normal and Alzheimer post mortem brain (1986) (6)
- Selective Loss of Cholinergic Receptors Following Unilateral Intracortical Injection of Volkensin (1997) (6)
- Neuronal Degeneration by Suicide Transport Following Injection of Volkensin into Rat Cerebral Cortex (1997) (5)
- An aspect of Alzheimer neuropathology after suicide transport damage. (1994) (5)
- Neuroanatomy/pathology and the interplay of neurotransmitters in moderate to severe Alzheimer disease (2005) (5)
- Tacrine may alter APP‐like protein levels in the lumbar CSF of Alzheimer patients (2001) (5)
- Genetic risk for Alzheimer’s disease influences neuropathology via multiple biological pathways (2020) (5)
- Genetic variation in the 5-HT2A receptor and altered neocortical [3H] ketanserin binding in Alzheimer's disease (2007) (5)
- Brains for Dementia Research: The Importance of Cohorts in Brain Banking (2019) (5)
- Epigenome-wide association study of human frontal cortex identifies differential methylation in Lewy body pathology (2021) (5)
- Effect of Li+ therapy and site of origin on cerebrospinal fluid beta-amyloid precursor protein derivatives. (1993) (5)
- Elevation of inactive cleaved annexin A1 in the neocortex is associated with amyloid, inflammatory and apoptotic markers in neurodegenerative dementias (2021) (4)
- Brain aging research at the close of the 20th century: from bench to bedside (2001) (4)
- Stage-Speci fi c Changes in Neurogenic and Glial Markers in Alzheimer ’ s Disease (2015) (4)
- On authorship and acknowledgments. (Editorial) (1992) (4)
- Differential alterations of neocortical GluN receptor subunits in patients with mixed subcortical ischemic vascular dementia and Alzheimer's disease. (2015) (4)
- Correction: Alzheimer’s disease polygenic risk score as a predictor of conversion from mild-cognitive impairment (2019) (4)
- Glutamate toxicity in rat cultured neurones: effects on amyloid precursor-like protein 2 (1999) (4)
- Alzheimer's Disease: From Acetylcholine to β–Amyloid (1996) (4)
- Factors affecting the beta-amyloid precursor in PC12 cells. (1993) (4)
- Brief communication CB 2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients (2013) (4)
- Distribution of Neurochemical Deficits in Alzheimer’s Disease (1990) (4)
- Alzheimer‐like pathology in trisomy 21 cerebral organoids amenable to pharmacological inhibition reveals BACE2 as a gene‐dose‐sensitive AD‐suppressor in human brain (2020) (4)
- Dynamin protein in stroke and vascular dementia (2014) (3)
- Non-serotonergic profiles of lobar atrophies. (1995) (3)
- Dopaminergic and Glutamatergic Systems in Alzheimer’s Disease (2005) (3)
- Relationship between beta-amyloid precursor protein, pyramidal neurones and astrocytes in human neocortex. (1993) (3)
- Cholinergic and Non-Cholinergic Neurotransmitter Hypotheses for Alzheimer’s Disease (1986) (3)
- Muscarinic M1 Receptor Coupling to G-protein is Intact in Parkinson's Disease Dementia. (2016) (3)
- Decreased immunoreactivities of neocortical AMPA receptor subunits correlate with motor disability in Lewy body dementias (2013) (3)
- Correction: Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain (2021) (3)
- New approaches to imaging based on effects of neurotoxins. (1997) (2)
- Glutamatergic Function in Alzheimer’s Disease (1997) (2)
- Randomized controlled trial of mibampator for behavioral and psychological symptoms of dementia: comments on the trial and thoughts for future studies (2013) (2)
- A SCIENTIFICALLY INFORMED BRAIN DONATION PROGRAMME: A DPUK INITIATIVE TO OFFER BRAIN DONATION TO PARTICIPANTS IN LONGITUDINAL COHORTS (2017) (2)
- Serotonergic profiles of lobar atrophies. (1995) (2)
- Correlations between synaptic proteins expression and clinico-pathological features in dementia with Lewy bodies and Parkinson?s disease dementia (2014) (2)
- BIOMARKERS FOR COGNITIVE DECLINE OF EARLY PARKINSON’S DISEASE (2014) (2)
- Neuronal pathology in relation to molecular biology and treatment of Alzheimer's disease. (1994) (2)
- The Brains for Dementia Research cohort: Demographics of people agreeing to regular assessment and brain donation for research (2012) (2)
- APOE epsilon 4 allele affects presynaptic, but not postsynaptic cholinergic markers in Alzheimer's disease neocortex (2006) (2)
- Spreading Pathologies Precede Cognitive Decline in Alzheimer’s Disease (2015) (2)
- Loss of serotonin 5-HT2A receptors in, the temporal cortex correlates with cognitive decline in Alzheimer's disease (2004) (2)
- A cortical pyramidal neurone neurotransmitter receptor that may affect beta-amyloid precursor protein. (1993) (2)
- Alzheimer's disease: from acetylcholine to beta-amyloid. A tribute to the work of Professor David M. Bowen. (1996) (2)
- Serotonin 5-HT2A receptor alterations in the postmortem neocortex of behaviorally assessed Alzheimer patients (2003) (2)
- Excitatory amino acid neurotransmitters, somatostatin and degenerate cortical neurons in Alzheimer's disease (1986) (2)
- Neurochemical pathology of cholinergic systems in neurodegenerative and neurdevelopmental disorders (2006) (2)
- RPT6, 20S α-6 AND α-3 PROTEASOME SUBUNIT LEVELS AND ASSOCIATION WITH COGNITIVE DECLINE IN ALZHEIMER’S DISEASE AND LEWY BODY DEMENTIAS (2017) (2)
- Factors affecting withdrawal and donation attrition in the brains for dementia research cohort (2018) (1)
- Soluble beta-amyloid precursor protein and pyramidal neuron loss. (1993) (1)
- Safety and Efficacy of Memantine Extended-Release in the Management of Alzheimer’s Disease (2013) (1)
- P4-386 Neuroprotective actions of an iron chelator against Alzheimer’s disease-relevant insults (2006) (1)
- Protease ‘Clipsin’ extract activity reflects demographic characteristics of human brain (1992) (1)
- Erratum to: Neuropsychiatric Symptoms in Patients with Dementias Associated with Cortical Lewy Bodies: Pathophysiology, Clinical Features, and Pharmacological Management (2014) (1)
- John Evelyn's diary; a selection from the diary (1963) (1)
- Neurochemistry of Alzheimer's Disease (2010) (1)
- The 5-HI1A antagonist, WAY 100635, ameliorates the cognitive impairment induced by fornix transection in the marmoset (2008) (1)
- P1-435 Essential oils as potential treatment for agitation in severe dementia: Elucidation of the pharmacological mechanism of Melissa and Lavender oils (2006) (1)
- Origins, interpretations and uses of high milk somatic cell counts (1993) (1)
- Neurochemistry of Severe Dementia (2005) (1)
- Current Neurotransmitter Strategies in AD Drug Development (1998) (1)
- Neurotransmitter Changes in Alzheimer's Disease: Relationships to Symptoms and Neuropathology (2002) (1)
- Correlations between clinical symptoms and biochemistry in lewy body dementia and Parkinson's disease dementia (2011) (0)
- Concordance between vascular risk factors during life with vascular postmortem pathology for a cohort of memory-impaired and cognitively normal individuals (2015) (0)
- An integrated epigenetic‐genetic study of neuropathology in the Brains for Dementia Research cohort (2020) (0)
- Association of proteasome subunit expression with reduced proteolytic activity in dementia with Lewy bodies and Parkinson's disease dementia (2008) (0)
- Correlation between the synaptic zinc transporter znt3 and alpha-synuclein in dementia (2015) (0)
- Neurochemical pathology of Parkinson’s disease dementia and dementia with Lewy bodies (2015) (0)
- depression . pharmacotherapy of Alzheimer ' s disease and neurotransmission : possible implications for Antemortem measurements of (0)
- INVESTIGATING GENETIC VARIATION IN ALZHEIMER’S DISEASE USING WHOLE-EXOME SEQUENCING (2017) (0)
- Selective upregulation of FynT tyrosine kinase in neurodegenerative dementia correlates well with tau pathology and neuroinflammation (2020) (0)
- P1-455 REGIONALWHITE MATTER HYPERINTENSITY CHANGES PREDICT COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT OF SUBCORTICALVASCULAR TYPE: A THREE-YEAR FOLLOW-UP STUDY (2017) (0)
- BRAINS FOR DEMENTIA RESEARCH: CONCORDANCE OF CLINICAL AND NEUROPATHOLOGICAL DIAGNOSES IN DECEASED PARTICIPANTS (2014) (0)
- S-16-1 Underlying neurotransmitter changes in Alzhelmer's disease (1995) (0)
- Brains for Dementia Research: The Importance of Cohorts in Brain Banking (2019) (0)
- Altered expression of synaptic proteins in the neocortex of Parkinson's disease with dementia (PDD) and dementia with Lewy bodies (DLB) (2010) (0)
- P3-022: Correlation of plasma biomarkers with clinical measures of Alzheimer's disease (2008) (0)
- S51RECALIBRATING THE EPIGENETIC CLOCK: APPLICATIONS FOR ASSESSING BIOLOGICAL AGEING IN THE HUMAN BRAIN (2019) (0)
- The cholinergic system and cognitive and noncognitive behavioral dysfunction in Alzheimer’s disease (2004) (0)
- Synaptic dysfunction and correlations with clinico-pathological features in dementia with Lewy bodies and Parkinson's disease dementia (2013) (0)
- Glucose modification and oxidation of macrophage migration inhibitory factor in Alzheimer’s disease (2016) (0)
- Brains for Dementia Research: Providing human tissue for dementia research to promote understanding of pathogenesis and aid drug discovery (2012) (0)
- 2642 FROM PHILIP FRANCIS 14 June 1820 (1989) (0)
- Reflections on the Abundance of Paper in Circulation and the Scarcity of Specie (2009) (0)
- M30 NEXT-GENERATION RNA SEQUENCING OF POST-MORTEM ANTERIOR CINGULATE AND DORSOLATERAL PREFRONTAL CORTICES TO IDENTIFY DIFFERENTIALLY EXPRESSED GENES IN PATHOLOGY-VERIFIED LEWY BODY DEMENTIA (2019) (0)
- Is improvement of cholinergic transmission the correct strategy for Alzheimer's disease? (1994) (0)
- The Francis Letters (2009) (0)
- P1-065: Oxidative load regulates amyloid burden in vitro and in vivo in an APP X PS1 transgenic mouse model of Alzheimer's disease (2008) (0)
- Ionotropic glutamatergic receptor alterations in the neocortex of Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB) (2010) (0)
- Proteasome and p62 protein impairment of the frontal cortex and anterior cingulate in Lewy body dementias (2012) (0)
- ANALYSIS OF UNRECOVERED BRAIN DONATIONS FROM A COHORT CONSENTING TO BRAIN DONATION AT DEATH AND DETAILED PSYCHOMETRIC ASSESSMENTS DURING LIFE (2016) (0)
- Biochemical correlates of clinical symptoms in dementia with Lewy bodies and Parkinson's disease dementia (2012) (0)
- P1-061: Markers of protein degradation in the B6C3-Tg(APPswe/PSEN1dE9) 85DboJ mouse on behalf of the addneuromed group (2008) (0)
- Cleaved Annexin A1 is elevated in neurodegenerative dementia and is associated with pathological burden of amyloid and inflammatory cytokines (2020) (0)
- Alzheimer's & Dementia: Translational Research & Clinical Interventions Cerebral amyloid angiopathy distribution in older people: a cautionary note --Manuscript (2021) (0)
- LINKING POLYGENIC RISK SCORES TO ALZHEIMER'S DISEASE GENES (2018) (0)
- Glutamatergic Hypoactivity in Alzheimer’s Disease: Investigative and Therapeutic Perspectives (1994) (0)
- Targeting serotonin/glutamate systems in Alzheimer's disease: Evidence from animal and human postmortem studies (1999) (0)
- Impairment of the proteasome on frontal cortex in lewy body dementia (2011) (0)
- Supplementary material (Baek et al. 2015) (2015) (0)
- The role of glutamate in CNS and the interplay with other neurotransmitters (2004) (0)
- Production of foamy virus vectors and their enhanced transduction of basal forebrain neuronal progenitor cells over MuLV-based vectors (2001) (0)
- Brains for Dementia Research: MMSE profile of the living cohort (2013) (0)
- P1-089: Biochemical characterization of the B6C3-Tg(APPswe,PSEN1dE9) 85Dbo/J mouse fed a pro-oxidant diet on behalf of the addneuromed group (2008) (0)
- Observations of extensive gene expression differences in the cerebellum and potential relevance to Alzheimer’s disease (2018) (0)
- Emergency and Essential Surgical Care Capacity across Primary, Secondary, and Tertiary Institutions in Meghalaya, India: A Cross-sectional Study (2016) (0)
- Electro-mechanical effects of calcium channel blockers, diltiazem, verapamil, and nisoldipine on canine atrial, ventricular, and purkinje fibers (1982) (0)
- Protection through the law (1964) (0)
- Alzheimer’s Disease: Role of Energy Metabolism and Treatment of Symptoms (1991) (0)
- Targeted bisulfite sequencing analysis of candidate genes associated with Alzheimer’s disease. (2022) (0)
- Corrigendum to “Association of a polymorphism in mitochondrial transcription factor A (TFAM) with Parkinson's disease dementia but not dementia with Lewy bodies” [Neurosci. Lett. 557 (2013) 177–180] (2014) (0)
- Low cell counts loom large. (1990) (0)
- INCREASED PSER129 α-SYNUCLEIN IS ASSOCIATED WITH SYNAPTIC DEFICITS IN DEMENTIA WITH LEWY BODIES (2017) (0)
- ANALYSIS OF PARTICIPANTS WITHDRAWING FROM A COHORT CONSENTING TO BRAIN DONATION AT DEATH AND DETAILED PSYCHOMETRIC ASSESSMENTS DURING LIFE (2017) (0)
- Alzheimer's and Parkinson's disease: anatomical, pathological and biochemical aspects (1986) (0)
- The neurochemistry of serotonin (5-HT) in Alzheimer's disease and BPSD (2003) (0)
- CLINICO-PATHOLOGIC ASSOCIATIONS IN DLB: RELEVANCE FOR DIAGNOSIS AND TREATMENT (2017) (0)
- Contents (2020) (0)
- Contribution of Alzheimer's disease and Lewy body pathology to behavior and cognition in Lewy body dementias (2013) (0)
- METABOLIC AND FUNCTIONNAL DEFICITS IN ALZHEIMER DISEASE IN RELATION TO TREATMENT (1995) (0)
- Increased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with β-amyloid burden and synaptic deficits in Lewy body dementias (2016) (0)
- Brains for dementia research: Use of telephone interview to gather assessment data (2015) (0)
- Protease "Clipsin" activity and beta-amyloid precursor protein degradation by Alzheimer brain. (1993) (0)
- [P3–078]: WITHDRAWN (2017) (0)
- ALZHEIMER’S DISEASE (AD) POLYGENIC RISK SCORE (PRS) AS A PREDICTOR OF CONVERSION FROM MILD COGNITIVE IMPAIRMENT (MCI) (2018) (0)
- The Rationale for Glutamatergic Therapy in Alzheimer's Disease (2007) (0)
- INCREASED PHOSPHORYLATION OF COLLAPSIN RESPONSE MEDIATOR PROTEIN-2 AT THR514 IS ASSOCIATED WITH ABETA BURDEN AND AXONAL DEFICITS IN DEMENTIA WITH LEWY BODIES (2016) (0)
- Preface: Lars Gustafson, Lund; Arne Brun, Lund (1999) (0)
- Synaptic protein expression is regulated by a pro-oxidant diet in APPxPS1 mice (2012) (0)
- AN INTEGRATED APPROACH TO U.K. BRAIN BANKING ALLOWING RESEARCHERS TO SELECT TISSUE WITH PRECISION: MRC U.K. BRAIN BANK NETWORK, CSOLS TRACKING SYSTEM AND BRAINS FOR DEMENTIA RESEARCH (2017) (0)
- PRELIMINARY ANALYSIS FROM RNA-SEQUENCING DERIVED FROM FIVE BRAIN REGIONS IN BDR SAMPLES (2017) (0)
- Brains for dementia research providing human tissue for dementia research to further understanding and aid treatment discovery (2011) (0)
- Implication of the serotonergic system in cognitive and non-cognitive disturbances associated to Alzheimer’s disease (2003) (0)
- Genetic risk for Alzheimer’s disease influences neuropathology and cognition via multiple biological pathways (2020) (0)
- The loss of neocortical P2Y(2) nucleotide receptors is associated with Alzheimer's disease neuropathology (2008) (0)
- M46 METHYLOMIC CONSEQUENCES OF POLYGENIC BURDEN FOR NEUROPSYCHIATRIC, NEURODEGENERATIVE AND NEUROLOGICAL DISORDERS (2019) (0)
- An iTRAQ-based proteomic analysis reveals dysregulation of neocortical synaptopodin in Lewy body dementias (2017) (0)
- P1-020: Behavioral and histochemical characterization of the effects of hippocampal injection of Abeta 1-42 in the rat (2008) (0)
- THE RELATIONSHIP OF SYNAPTIC PROTEINS WITH AGE IN DOWN SYNDROME (2017) (0)
- RELATIONSHIP BETWEEN PATHOLOGY SCORES, CLINICAL DATA AND EXPRESSION LEVELS OF PROTEASOME SUB-UNITS IN ALZHEIMER’S DISEASE AND LEWY BODY DEMENTIAS (2017) (0)
- 5-HTTPR is associated with altered neocortical [H-3]citalopram binding and anxiety in Alzheimer disease (2003) (0)
- Rationale for Glutamatergic and Cholinergic Approaches for the Treatment of Alzheimer’s Disease (2008) (0)
- Brains for Dementia Research: Characteristics and cognitive scores associated with the brain tissue available to researchers (2013) (0)
- Increased Levels of Brain Adrenomedullin in the Neuropathology of Alzheimer’s Disease (2017) (0)
- P2-226: Association of proteasome subunit expression with reduced proteolytic activity in dementia with Lewy bodies and Parkinson's disease dementia (2008) (0)
- Assessment of the contribution of common genetic variants associated with Alzheimer’s disease on neuropathological burden and clinical characteristics in the Brains for Dementia Research cohort (2020) (0)
- Randomized controlled trial of mibampator for behavioral and psychological symptoms of dementia: comments on the trial and thoughts for future studies – ADDENDUM (2014) (0)
- P4-064: Neuroleptic medication is associated with selective alterations in VCSF Aβ40 and tau in patients with intractable unipolar depression (2008) (0)
- The Rationale for Development of Cholinergic Therapies in ad (1998) (0)
- Noradrenergic changes and aggressive behaviour in patients with dementia (2000) (0)
- G-protein coupling to muscarinic M1 receptors is differentially affected in neurodenegerative dementias (2012) (0)
- Mixed brain pathologies account for most dementia in the UK’s Brains for Dementia Research cohort (2020) (0)
- Decreased JNK3 levels are associated with amyloid plaque and neurofibrillary tangles in dementia patients (2020) (0)
- A PILOT STUDY EVALUATING VIDEO-BASED PSYCHOMETRIC ASSESSMENT IN VOLUNTEER BRAIN DONORS AGED 65+ YEARS (2016) (0)
- COMPARING BRAAK STAGE IN BRAIN DONORS WITH AND WITHOUT SUBJECTIVE COGNITIVE IMPAIRMENT (SCI) DURING LIFE (2017) (0)
- Author and Subject Index (1998) (0)
- Erratum to: Proteasome inhibition leads to early loss of synaptic proteins in neuronal culture (2013) (0)
- Altered relaxin family receptors RXFP1 and RXFP3 in the neocortex of depressed Alzheimer’s disease patients (2015) (0)
- David Bowen, 1940-2011 OBITUARY (2011) (0)
- Clusterin associates specifically with beta-amyloid 40 Alzheimer's disease brain tissue (2013) (0)
- BRAINS FOR DEMENTIA RESEARCH: ASSESSMENT OF DEPRESSION IN THE COHORT (2014) (0)
- P1-087 CHARACTERIZATION OF AMYLOID DEPOSITION IN TgCRND8 MOUSE MODEL (2008) (0)
- Cholinergic and Serotonergic Systems in Severe Dementia (2006) (0)
This paper list is powered by the following services:
Other Resources About Paul T. Francis
What Schools Are Affiliated With Paul T. Francis?
Paul T. Francis is affiliated with the following schools:
